Unknown

Dataset Information

0

Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.


ABSTRACT: Although trastuzumab has succeeded in breast cancer treatment, acquired resistance is one of the prime obstacles for breast cancer therapies. There is an urgent need to develop novel HER2 antibodies against trastuzumab resistance. Here, we first rational designed avidity-imporved trastuzumab and pertuzumab variants, and explored the correlation between the binding avidity improvement and their antitumor activities. After characterization of a pertuzumab variant L56TY with potent antitumor activities, a bispecific immunoglobulin G-like CrossMab (Tras-Permut CrossMab) was generated from trastuzumab and binding avidity-improved pertuzumab variant L56TY. Although, the antitumor efficacy of trastuzumab was not enhanced by improving its binding avidity, binding avidity improvement could significantly increase the anti-proliferative and antibody-dependent cellular cytotoxicity (ADCC) activities of pertuzumab. Further studies showed that Tras-Permut CrossMab exhibited exceptional high efficiency to inhibit the progression of trastuzumab-resistant breast cancer. Notably, we found that calreticulin (CRT) exposure induced by Tras-Permut CrossMab was essential for induction of tumor-specific T cell immunity against tumor recurrence. These data indicated that simultaneous blockade of HER2 protein by Tras-Permut CrossMab could trigger CRT exposure and subsequently induce potent tumor-specific T cell immunity, suggesting it could be a promising therapeutic strategy against trastuzumab resistance.

SUBMITTER: Zhang F 

PROVIDER: S-EPMC4404837 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.

Zhang Fan F   Zhang Jie J   Liu Moyan M   Zhao Lichao L   LingHu RuiXia R   Feng Fan F   Gao Xudong X   Jiao Shunchang S   Zhao Lei L   Hu Yi Y   Yang Junlan J  

Oncoimmunology 20150122 3


Although trastuzumab has succeeded in breast cancer treatment, acquired resistance is one of the prime obstacles for breast cancer therapies. There is an urgent need to develop novel HER2 antibodies against trastuzumab resistance. Here, we first rational designed avidity-imporved trastuzumab and pertuzumab variants, and explored the correlation between the binding avidity improvement and their antitumor activities. After characterization of a pertuzumab variant L56TY with potent antitumor activi  ...[more]

Similar Datasets

| S-EPMC4011918 | biostudies-literature
| S-EPMC4327899 | biostudies-literature
| S-EPMC2896450 | biostudies-literature
| S-EPMC7218915 | biostudies-literature
| S-EPMC3446380 | biostudies-literature
| S-EPMC10643871 | biostudies-literature
| S-EPMC2722050 | biostudies-other
| S-EPMC7409266 | biostudies-literature
| S-EPMC8623301 | biostudies-literature
| S-EPMC5584169 | biostudies-literature